1.65
+0.02(+1.23%)
Currency In USD
Address
188 East Blaine Street
Seattle, WA 98102
United States of America
Phone
206 701 7914
Website
Sector
Healthcare
Industry
Biotechnology
Employees
328
First IPO Date
February 04, 2021
| Name | Title | Pay | Year Born |
| Dr. Steven D. Harr M.D. | President, Chief Executive Officer & Director | 1.04M | 1970 |
| Mr. Bernard J. Cassidy J.D. | Executive Vice President, General Counsel & Corporate Secretary | 491,388 | 1955 |
| Dr. Yuko Soneoka J.D., Ph.D. | Head of Intellectual Property | 0 | N/A |
| Dr. Gary Meininger M.D. | Chief Medical Officer | 0 | N/A |
| Dr. Sonja Schrepfer M.D., Ph.D. | Senior Vice President & Head of Hypoimmune Platform | 0 | 1975 |
| Ms. Susan Wyrick | Acting Chief Financial Officer, Treasurer, Principal Accounting Officer and Senior Vice President of Finance & Accounting | 0 | 1973 |
| Mr. Snehal Patel | Senior Vice President & Chief Technical Officer | 0 | N/A |
| Dr. Dhavalkumar D. Patel M.D., Ph.D. | Executive Vice President & Chief Scientific Officer | 0 | 1961 |
| Mr. John Gerecitano M.D., Ph.D. | Head of Oncology Research & Development | 0 | N/A |
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.